Seven Fleet Capital Management LP Takes Position in Compass Therapeutics, Inc. $CMPX

Seven Fleet Capital Management LP acquired a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 568,747 shares of the company’s stock, valued at approximately $3,054,000. Compass Therapeutics accounts for 2.3% of Seven Fleet Capital Management LP’s portfolio, making the stock its 5th largest position.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Russell Investments Group Ltd. boosted its holdings in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the last quarter. Creative Planning purchased a new stake in Compass Therapeutics in the 2nd quarter valued at $30,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $32,000. Strs Ohio acquired a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $34,000. Finally, CIBC Bancorp USA Inc. purchased a new position in Compass Therapeutics in the third quarter worth approximately $37,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CMPX has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Monday, April 20th. Raymond James Financial lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. Stifel Nicolaus set a $6.00 price target on shares of Compass Therapeutics in a research report on Monday, June 1st. Jefferies Financial Group reiterated a “buy” rating and issued a $9.00 price objective on shares of Compass Therapeutics in a research note on Thursday, March 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.91.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $2.02 on Friday. Compass Therapeutics, Inc. has a 1-year low of $1.61 and a 1-year high of $6.88. The stock has a market cap of $363.78 million, a PE ratio of -4.93 and a beta of 0.89. The stock’s fifty day moving average is $2.90 and its two-hundred day moving average is $4.66.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, research analysts expect that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.